In Silico Prediction and Pharmacokinetic Comparison of Ursodeoxycholic Acid and Obeticholic Acid in the Management of Primary Biliary Cholangitis
Abstract
Background: Primary Biliary Cholangitis (PBC) is a persistent liver disease. Ursodeoxycholic acid is used as a first-line treatment for the past two decades. However, concurrent use of Ursodeoxycholic acid reported with a severe adverse drug reaction. Obeticholic acid has been started utilizing as monotherapy and also with Ursodeoxycholic acid in a patient who is intolerant to Ursodeoxycholic acid therapy. We primarily aimed to compare the pharmacokinetic & toxicity profiles of Ursodeoxycholic acid and Obeticholic acid using in silico methods.
Method: The pharmacokinetic profile of UDCA & OCA was observed from PKCSM server online database, OSIRIS® property Explorer, T.E.S.T. (Toxicity estimation software tool) & Molinspiration® is used to estimate the drug toxicity profiles.
Result: This computer-aided response provides a great understanding and creates a gap between the theoretical and clinical evidence for UDCA & OCA's preference in PBC management.
Conclusion: Co-administration of Obeticholic acid with Ursodeoxycholic acid will be an effective treatment for PBC in patients with UDCA intolerants. However, both medications are well-recognized substrates of the CYP3A4 enzyme and may lead to unintended drug interactions and side effects.
Keywords: Primary Biliary Cholangitis, Obeticholic acid, Ursodeoxycholic acid, CYP3A4, Drug Interactions, Pharmacokinetics.
Keywords:
Primary Biliary Cholangitis, Obeticholic acid, Ursodeoxycholic acid, CYP3A4, Drug Interactions, PharmacokineticsDOI
https://doi.org/10.22270/jddt.v11i2-S.4669References
Kumagi T, Heathcote E. Primary biliary cirrhosis. Orphanet J Rare Dis 2008; 3:1.
Marzioni M, Bassanelli C, Ripellino C, Urbinati D, Alvaro D, Epidemiology of primary biliary cholangitis in Italy: Evidence from a real-world database. Dig Liver Dis 2019; 51(5):724-729.
Borman M, Swain MG. Changing epidemiology and natural history of primary biliary cirrhosis. Clin Liver Dis (Hoboken) 2014; 10,3(1):12-14.
Marschall HU, Henriksson I, Lindberg S, Söderdahl F, Thuresson M, Wahlin S, Ludvigsson, JF. Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort. Sci Rep 2019, 8,9(1):11525.
Paumgartner G. Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression. J Hepatol 2003; 39(1):112-4.
Kotb M.A. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. Int J Mol Sci 2012; 13(7):8882-914.
Fiorucci S, Di Giorgio C, Distrutti E. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders. Handb Exp Pharmacol 2019; 256:283-295.
Modica S, Petruzzelli M, Bellafante E, et al. Selective activation of nuclear bile acid receptor F.X.R. in the intestine protects mice against cholestasis. Gastroenterology 2012; 142(2):355-65.
Shah RA, Kowdley KV. Current and potential treatments for primary biliary cholangitis. Lancet Gastroenterol Hepatol 2020 5(3):306-315.
Cabrera D, Arab JP, Arrese M. UDCA, NorUDCA, and T.U.D.C.A. in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications. Handb Exp Pharmacol 2019; 256:237-264.
Ikegami T, Matsuzaki Y. Ursodeoxycholic acid: Mechanism of action and novel clinical applications. Hepatol Res 2008; 38(2):123-131.
Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy ofursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis 2004; 8(1):67-vi.
Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. Journal of medicinal chemistry 2015; 58(9):4066–4072.
Ayati A, Falahati M, Irannejad H, Emami S. Synthesis, in vitro antifungal evaluation and in silico study of 3-azolyl-4-chromanone phenylhydrazones. Daru 2012; 20(1):46.
Rashid M. Design, synthesis and ADMET prediction of bis-benzimidazole as anticancer agent. Bioorg Chem 2020; 96:103576.
Osman W, Ismail E.M.O.A, Shantier SW, Mohammed MS, Mothana RA, Muddathir A, Khalid HS. In silico assessment of potential leads identified from Bauhinia rufescens Lam. as α-glucosidase and α-amylase inhibitors. J Recept Signal Transduct Res 2021; 41(2):159-169.
Martin T, P. Harten, D. Young. TEST (Toxicity Estimation Software Tool) Ver 4.1. U.S. Environmental Protection Agency, Washington, DC, E.P.A./600/C-12/006, 2012.
Husain A, Ahmad A, Khan SA, Asif M, Bhutani R, Al-Abbasi FA. Synthesis, molecular properties, toxicity and biological evaluation of some new substituted imidazolidine derivatives in search of potent anti-inflammatory agents. Saudi Pharm J 2016; 24(1):104-14.
Kumar N, Mishra SS, Sharma CS, Singh HP, Pandiya H. In silico Pharmacokinetic, Bioactivity and Toxicity Evaluation of Some Selected Anti-Ulcer Agents. Int J Pharm Sci Res 2017; 9(2):68-71.
Hassan M, Ashraf Z, Abbas Q, Raza H, Seo SY. Exploration of Novel Human Tyrosinase Inhibitors by Molecular Modeling, Docking and Simulation Studies. Interdiscip Sci 2018; 10(1):68-80.
Laschtowitz A, de Veer RC, Van der Meer AJ, Schramm C. Diagnosis and treatment of primary biliary cholangitis. United European Gastroenterol J 2020; 8(6):667-674.
Mudaliar S, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145(3):574-82.
Nevens F, et al. POISE Study Group. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med 2016; 375(7):631-43.
Sabarathinam S, Vijayakumar TM, A short exploration of selected sensitive CYP3A4 substrates (Probe Drug). Drug Metabolism Letters, 2020, 14:1.
Published
Abstract Display: 1315 
PDF Downloads: 683 PDF Downloads: 321 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.